MOLDTKPAC
Mold-Tek Packaging share price & financials
- Price
- ₹695.6
- Market cap
- ₹2.2k Cr
- Sector
- Capital Goods
- Calls analysed
- 6
Mold-Tek Packaging Limited Q1 FY27
What went well
- Turnover crossed INR300 crores in Q1 FY27, indicating strong top-line performance.
- Per kg EBITDA significantly increased to INR46.7, surpassing the historical INR40-42 range, driven by consolidation efforts and improved efficiencies.
- High-value segments like Pharma (41% value, 38% volume growth) and Food & FMCG (24.2% volume growth) showed robust expansion.
What to watch
- Lube segment volume declined by 17% due to base oil unavailability, impacting overall volume growth.
- Qpack segment growth was only 2% in volume, attributed to price sensitivity and increased raw material costs affecting key industries.
What Mold-Tek Packaging Limited does
Mold-Tek Packaging manufactures rigid plastic packaging - pails, containers, closures and labels - using injection moulding and its pioneered in-mold labelling (IML) process, in which a photographic label is fused into the container wall during moulding for a fully recyclable, tamper-evident finish. It is backward-integrated into its own tool room, designing and building its own moulds and robots in-house, which gives it a cost edge in the packaging industry. It sells to branded manufacturers across the paints, lubricants, food & FMCG and pharmaceutical industries, with long-standing supply relationships with customers such as Asian Paints, Castrol, Shell, Hindustan Unilever and Mondelez.
Segments
- Paints
- Lubricants (Lubes)
- Food & FMCG
- Pharma Packaging
- Q-Pack / Bulk Packs (Square Packs)
- Installed injection moulding capacity
- 63,000 TPA
- Manufacturing units
- 10 plants across 8 Indian states (Telangana, Maharashtra, Karnataka, Tamil Nadu, Haryana, Uttar Pradesh, Andhra Pradesh, Dadra & Nagar Haveli and Daman & Diu)
- ISO certified plants
- 10
- Injection moulding machines
- 175+
- In-house designed and built moulds/robots
- 1000+
- Stock points (depots)
- 2, pan-India
Guidance record · Q1 FY27
what the last two calls moved 24 tracked 4 delivered 3 missed 17 open- ROCE went quiet said Q4 FY26 Promised: 13.5-14% Q1 FY27: Not mentioned in the earnings call.
- EBITDA per kg revised up said Q4 FY26 Promised: INR42.5-43 Q1 FY27: Achieved Rs 46.7 in Q1. Raised full-year guidance to Rs 44-45.
- Pharma Revenue delivered said Q4 FY25 Promised: Rs 30-35 crores for FY26 Q4 FY26: Achieved Rs 34.4 crores for FY26
All 24 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 24.5%, net profit up 18.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 191 | 191 | 203 | 241 | 210 +10% | 198 +4% | 238 +17% | 300 +24% |
| EBITDA | 34 | 34 | 38 | 47 | 39 +15% | 38 +12% | 48 +26% | 56 +19% |
| Net profit | 14 | 14 | 16 | 22 | 15 +7% | 14 +0% | 21 +31% | 26 +18% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −17.9% 1Y
1Y: ₹824.35 on 10 Sept 2025 → ₹676.45. High ₹832.4 (18 Sept 2025), low ₹472.65 (24 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- −4.8%
- 27 Jul
- Q4 FY26
- −1.3%
- 11 May
- Q3 FY26
- +0.9%
- 9 Feb
- Q2 FY26
- +1.1%
- 4 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 6.7% a year over 3 years, FY23 to FY26. Operating margin widened to 19.4%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹731 Cr | ₹698 Cr | ₹782 Cr | ₹887 Cr |
| Operating profit | ₹135 Cr | ₹133 Cr | ₹142 Cr | ₹172 Cr |
| Operating margin | 18.5% | 19.1% | 18.2% | 19.4% |
| Interest | ₹4 Cr | ₹8 Cr | ₹14 Cr | ₹17 Cr |
| Depreciation | ₹29 Cr | ₹38 Cr | ₹49 Cr | ₹59 Cr |
| Net profit | ₹80 Cr | ₹67 Cr | ₹61 Cr | ₹72 Cr |
| Net margin | 10.9% | 9.6% | 7.8% | 8.1% |
| Cash from operations | ₹152 Cr | ₹79 Cr | ₹110 Cr | ₹125 Cr |
| Free cash flow | ₹5 Cr | ₹-56 Cr | ₹-33 Cr | ₹7 Cr |
| ROCE | 19.0% | 14.0% | 12.0% | 13.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹14 Cr | ₹16 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
| Reserves | ₹242 Cr | ₹441 Cr | ₹542 Cr | ₹578 Cr | ₹652 Cr | ₹673 Cr |
| Borrowings | ₹108 Cr | ₹44 Cr | ₹47 Cr | ₹126 Cr | ₹222 Cr | ₹215 Cr |
| Other liabilities | ₹72 Cr | ₹73 Cr | ₹90 Cr | ₹99 Cr | ₹129 Cr | ₹154 Cr |
| Total liabilities | ₹436 Cr | ₹574 Cr | ₹696 Cr | ₹820 Cr | ₹1.0k Cr | ₹1.1k Cr |
| Fixed assets | ₹239 Cr | ₹262 Cr | ₹376 Cr | ₹477 Cr | ₹579 Cr | ₹623 Cr |
| Capital work in progress | ₹12 Cr | ₹15 Cr | ₹17 Cr | ₹11 Cr | ₹46 Cr | ₹14 Cr |
| Investments | ₹9 Cr | ₹17 Cr | ₹52 Cr | ₹38 Cr | ₹38 Cr | ₹22 Cr |
| Other assets | ₹177 Cr | ₹281 Cr | ₹251 Cr | ₹294 Cr | ₹355 Cr | ₹399 Cr |
| Total assets | ₹436 Cr | ₹574 Cr | ₹696 Cr | ₹820 Cr | ₹1.0k Cr | ₹1.1k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
What the price assumes
Growth trapTo justify its price of ₹676, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~-3%. At that growth it is worth ₹193 — downside of 71%.
- Growth the price implies
- 20.1% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -3.5% a year
- net profit, FY23–FY26 · EPS -3.3%
- The gap
- 0.2 pp
- -71% downside if it only repeats history
All earnings calls (6)
Read the Q1 FY27 call →Learn to analyse Mold-Tek Packaging Limited
Guides on how to read this kind of business and the numbers that matter.